Cancer immunotherapy is revolutionizing clinical oncology. However, it is still unclear why only a subgroup of patients presents durable clinical responses following treatment. The identification of markers to accurately predict patients responding to this type of therapy is therefore a high priority. My laboratory focuses on the development and application of a new state-of-the-art analytical technology called SWATH / DIA mass spectrometry.
This technology makes it possible to measure in a unique way important molecules involved in the functioning of the immune system during its fight against cancer. Using this technology, we aim to predict the effectiveness of cancer immunotherapy on a personalized basis and improve its effectiveness through the development of therapeutic cancer vaccines for individual cancer patients.